Koselugo (selumetinib) was largely forgotten after failing Phase III trials in thyroid and lung cancer, as well as uveal melanoma, but its approval in Europe for inoperable plexiform neurofibromas in patients with neurofibromatosis type 1, which follows a US approval for the rare condition last year, has breathed new life into the once-lauded MEK 1/2 inhibitor.

The German drug maker is spending CHF450m to acquire T3, which is focused on developing live bacteria to treat cancers.

The drug maker will spend up to $610m to acquire Caraway, with a lead product candidate targeting TRPML1, a pathway implicated in a number of neurodegenerative diseases.